Aethlon Medical, Inc. (AEMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aethlon Medical, Inc. (AEMD) Healthcare & Pipeline Overview

Aethlon Medical, Inc. is a clinical-stage medical technology company specializing in developing the Aethlon Hemopurifier, an innovative device targeting the removal of tumor-derived exosomes and life-threatening viruses from the bloodstream, positioning it within the niche market of advanced therapeutic devices for critical and oncologic care.

What Is the Investment Thesis for AEMD?

Aethlon Medical's investment thesis centers on the potential of its Aethlon Hemopurifier to address critical unmet needs in treating life-threatening diseases. The device's ability to remove tumor-derived exosomes and viruses from the bloodstream presents a novel approach to immunotherapy and viral infection management. Key value drivers include successful completion of clinical trials, regulatory approvals, and strategic partnerships for commercialization. The collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center provides a platform for further research and validation of the Hemopurifier's efficacy, especially in head and neck cancer. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and market acceptance of its technology. The company's small size and limited resources also pose challenges to large-scale commercialization.

Based on FMP financials and quantitative analysis

AEMD Key Highlights

Aethlon Hemopurifier is in clinical stage development targeting life-threatening viruses and tumor-derived exosomes.

• Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center focuses on studies related to head and neck cancer.
• The company's technology aims to address unmet needs in critical care and cancer therapy.
• Aethlon Medical was founded in 1999, demonstrating over two decades of research and development in medical technology.
• The company operates with a lean structure of 14 employees, reflecting a focused approach to innovation.

Who Are AEMD's Competitors?

AEMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AEMD's Key Strengths?

Innovative Hemopurifier technology targeting unmet medical needs.

• Collaboration with a leading cancer center.
• Potential for broad application in various diseases.
• Proprietary technology with patent protection.

What Are AEMD's Weaknesses?

Limited financial resources and small company size.

• Reliance on successful clinical trial outcomes.
• Regulatory hurdles and market acceptance risks.
• Limited commercialization experience.

What Could Drive AEMD Stock Higher?

Completion of ongoing clinical trials for the Aethlon Hemopurifier in specific disease indications.

• Potential regulatory approvals from the FDA or other international regulatory agencies.
• Continued collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for research and development.
• Publication of clinical data in peer-reviewed journals.

What Are the Key Risks for AEMD?

Financial-distress signal — its Altman Z-Score of -41.96 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Delays or rejection of regulatory approvals.
• Competition from alternative therapies and medical devices.
• Limited financial resources and dependence on external funding.
• Market acceptance and adoption of the Hemopurifier technology.

What Are the Growth Opportunities for AEMD?

• Expansion into New Therapeutic Areas: Aethlon Medical has the opportunity to broaden the application of its Hemopurifier technology to address other diseases characterized by the presence of harmful substances in the bloodstream. This could include autoimmune disorders or other types of cancer beyond head and neck cancer. The market size for these expanded applications could reach several billion dollars, contingent on successful clinical trials and regulatory approvals. Timeline for expansion is estimated at 3-5 years, requiring significant investment in research and development.
• Strategic Partnerships for Commercialization: Forming strategic alliances with established pharmaceutical or medical device companies could accelerate the commercialization of the Aethlon Hemopurifier. These partnerships could provide access to funding, distribution networks, and regulatory expertise. The potential market reach through partnerships is global, with a timeline of 2-3 years for establishing key alliances. This strategy would leverage the partner's existing infrastructure to maximize market penetration.
• Geographic Expansion: Aethlon Medical can explore opportunities to expand its market presence beyond the United States. Europe and Asia represent significant markets for medical devices, particularly in countries with advanced healthcare systems. The timeline for geographic expansion is estimated at 3-5 years, requiring regulatory approvals in each target market. The potential market size in these regions could be substantial, driven by increasing healthcare spending and aging populations.
• Development of Companion Diagnostics: The development of companion diagnostics to identify patients most likely to benefit from the Aethlon Hemopurifier could enhance its clinical utility and market adoption. These diagnostics could help personalize treatment and improve patient outcomes. The market for companion diagnostics is growing rapidly, driven by the increasing focus on precision medicine. The timeline for developing and validating companion diagnostics is estimated at 2-3 years.
• Advancement of Exosome Research: Aethlon Medical can leverage its expertise in exosome removal to advance research in exosome biology and their role in disease progression. This could lead to the development of new diagnostic and therapeutic applications beyond the Hemopurifier. The market for exosome-based technologies is still emerging, but has significant potential for future growth. Timeline for significant research advancements is estimated at 3-5 years, requiring ongoing investment in basic science research.

What Threats Does AEMD Face?

• Competition from established medical device companies.
• Unfavorable regulatory changes and reimbursement policies.
• Clinical trial failures and unexpected safety issues.
• Technological obsolescence.

What Are AEMD's Competitive Advantages?

• Proprietary Hemopurifier technology with patents and intellectual property protection.
• First-mover advantage in the niche market of exosome and virus removal.
• Established collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center.
• Clinical data supporting the safety and efficacy of the Hemopurifier.

What Does AEMD Do?

Founded in 1999 and based in San Diego, California, Aethlon Medical, Inc. is a medical technology company dedicated to creating innovative solutions for diagnosing and treating life-threatening diseases. The company's primary focus is the development of the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device designed to remove harmful substances from the human circulatory system. This device targets a range of threats, including tumor-derived exosomes and life-threatening viruses such as COVID-19 and its variants. The Aethlon Hemopurifier works by capturing and removing these harmful substances directly from the bloodstream, offering a potential treatment option for patients facing severe viral infections and cancer-related complications. The company's collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center underscores its commitment to advancing research and development in the field of oncology, specifically in the context of head and neck cancer. Aethlon Medical continues to focus on clinical trials and regulatory approvals to bring its Hemopurifier technology to market, addressing unmet needs in critical care and cancer therapy.

What Products and Services Does AEMD Offer?

• Develop the Aethlon Hemopurifier, an immunotherapeutic device.
• Focus on removing tumor-derived exosomes from the bloodstream.
• Target life-threatening viruses, including COVID-19 and its variants.
• Collaborate with medical centers for clinical studies.
• Research and develop technologies for diagnosing and treating life-threatening diseases.
• Aim to improve patient outcomes in critical care and cancer therapy.

How Does AEMD Make Money?

• Develop and commercialize the Aethlon Hemopurifier.
• Generate revenue through sales of the Hemopurifier device.
• Establish partnerships with healthcare providers and research institutions.
• Seek regulatory approvals for expanded applications of the technology.

What Industry Does AEMD Operate In?

Aethlon Medical operates within the medical device industry, which is characterized by rapid technological advancements and stringent regulatory requirements. The market for immunotherapeutic devices is growing, driven by the increasing prevalence of cancer and infectious diseases. Aethlon's Hemopurifier aims to address a specific niche within this market by targeting the removal of tumor-derived exosomes and viruses from the bloodstream. Competition includes companies developing alternative therapies and devices for cancer and viral infections. The industry is subject to evolving regulatory standards and reimbursement policies, which can impact market access and adoption of new technologies.

Who Are AEMD's Key Customers?

• Hospitals and critical care units treating patients with severe viral infections.
• Oncology centers treating patients with cancer-related complications.
• Research institutions conducting studies on exosomes and viral diseases.
• Patients requiring removal of harmful substances from their bloodstream.

Aethlon Medical, Inc. Financial Trajectory

Aethlon Medical, Inc. (AEMD) reported $0 in revenue for Q1 FY2027, based on the latest filing compared to the prior quarter. The company recorded a net loss of $1.5M, with diluted EPS of $-4.02. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, AEMD averaged $-2.93 in diluted EPS.

Company Profile

Aethlon Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO James Frakes. AEMD has traded publicly since 1999.

How Aethlon Medical, Inc. Is Valued

Analyst price targets span from $1.50 to $1.50, with a consensus of $1.50. At the current price of $1.56, that implies roughly 4% downside from the consensus target. Relative to its peer group, AEMD's quantitative score of 28/100 is below the peer average of 71/100.

Aethlon Medical, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.96 places it in the distress zone, a signal of elevated financial risk.

Aethlon Medical, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1368.5% below estimates on average.

Over the past six months, Aethlon Medical, Inc. insiders filed 10 SEC Form 4 transactions — 6 sales and 4 purchases. On net that is roughly 81K shares acquired (about $194K) — insiders putting money in tends to read as conviction.

AEMD Financials

AEMD Latest News

AEMD Analyst Consensus

AEMD MoonshotScore

What Investors Ask About Aethlon Medical, Inc. (AEMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources